ASH 2018: New data presented on synergistic action of LIMK inhibitors with BCR-ABL TKIs

At the 60th American Society of Hematology Congress, Pr Thorsten Braun presented the work performed by the Leukemia Translational Laboratory, Saint Louis Hospital , Paris, on selective LIM Kinase 1/2 inhibitors for combination treatment of BCR-ABL1 Acute Lymphoblastic Leukemia.

This new data includes positive results from in vitro experiments and in vivo models, obtained when combining administration of CEL_Amide with BCR-ABL1 Tyrosine Kinase Inhibitors including nilotinib.

It reinforces the rationale for looking into LIM Kinase inhibition as synergistic therapeutic agents with TKIs targeting TKRs upstream of the Rho-GTPase pathway, such as FLT3, C-KIT and BCR-ABL.

The ASH 2018 Poster can downloaded here Poster BCR-ABl LIMK ASH 2018

read more



EU Lead Factory and CELLIPSE achieve Collaboration Milestone

EU Lead Factory (ELF) and CELLIPSE announced today completion of the 1st phase of their collaboration program to identify hits against an undisclosed innovative therapeutic target that is involved in cytoskeleton regulation.

The qualified hit list delivered to CELLIPSE was obtained from a screening program on ELF’s Joint European Compound Library that included more than 400,000 (now 450,000) compounds. The screening effort was led by Pivot Park Screening Centre, with support from the University of Oxford, University of Dundee, Newhouse and CELLIPSE.

read more